| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MS4A1 |
| Uniprot No | P11836 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-297aa |
| 氨基酸序列 | MTTPRNSVNGTFPAEPMKGPIAMQSGPKPLFRRMSSLVGPTQSFFMRESK TLGAVQIMNGLFHIALGGLLMIPAGIYAPICVTVWYPLWGGIMYIISGSL LAATEKNSRKCLVKGKMIMNSLSLFAAISGMILSIMDILNIKISHFLKME SLNFIRAHTPYINIYNCEPANPSEKNSPSTQYCYSIQSLFLGILSVMLIF AFFQELVIAGIVENEWKRTCSRPKSNIVLLSAEEKKEQTIEIKEEVVGLT ETSSQPKNEEDIEIIPIQEEEEEETETNFPEPPQDQESSPIENDSSP |
| 预测分子量 | 58 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MS4A1(CD20)重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Epitope mapping of CD20 using recombinant protein fragments*
**作者**：Anderson et al.
**摘要**：通过构建MS4A1基因不同区域的重组蛋白片段，研究抗CD20单克隆抗体(如利妥昔单抗)的结合表位，确认其表位位于CD20的第二个胞外结构域(EC2)，为抗体药物设计提供依据。
2. **文献名称**：*Structural characterization of recombinant CD20 in lipid nanodiscs*
**作者**：Beers et al.
**摘要**：利用重组表达技术纯化MS4A1蛋白，结合冷冻电镜解析其膜嵌入结构，揭示了CD20的四聚体构象及其跨膜区相互作用，阐明了其作为B细胞标志物的分子基础。
3. **文献名称**：*Development of a recombinant CD20-based ELISA for autoimmune disease diagnosis*
**作者**：Müller et al.
**摘要**：通过哺乳动物细胞系统表达重组MS4A1蛋白，建立高灵敏ELISA检测方法，用于系统性红斑狼疮等疾病患者血清中抗CD20自身抗体的检测，提升临床诊断准确性。
---
这些研究涵盖了MS4A1重组蛋白在表位分析、结构解析及诊断应用中的关键作用。如需具体文献信息，可进一步提供DOI或期刊名称。
**Background of MS4A1 Recombinant Protein**
The MS4A1 gene encodes CD20. a cell surface protein predominantly expressed on B lymphocytes. CD20 plays a critical role in B-cell activation, differentiation, and calcium signaling, though its precise molecular mechanisms remain partially understood. It is a non-glycosylated phosphoprotein with four transmembrane domains, forming a tetrameric structure that may function as a calcium channel or interact with other signaling molecules.
MS4A1-derived CD20 is a well-established therapeutic target in B-cell malignancies and autoimmune disorders. Monoclonal antibodies like rituximab, ofatumumab, and obinutuzumab bind to CD20. enabling targeted depletion of malignant or dysregulated B cells. To support research and drug development, recombinant MS4A1 protein is produced using heterologous expression systems (e.g., mammalian cells like CHO or HEK293). This recombinant protein retains the extracellular domains critical for antibody binding and is utilized in assays to study drug-target interactions, screen therapeutic candidates, or develop diagnostic tools.
In research, MS4A1 recombinant protein aids in elucidating CD20's structural and functional properties, including its role in B-cell receptor signaling and immune evasion mechanisms. It also serves as a reference antigen in immunoassays, flow cytometry, or vaccine development. Additionally, it supports the generation of CD20-specific antibodies for clinical or experimental use.
The development of MS4A1 recombinant protein underscores its importance in advancing both basic immunology and translational medicine, particularly in improving therapies for diseases like non-Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple sclerosis.
×
